See more : Two Harbors Investment Corp. (TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Qualigen Therapeutics, Inc. (QLGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Qualigen Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CA Cultural Technology Group Limited (1566.HK) Income Statement Analysis – Financial Results
- PT Baramulti Suksessarana Tbk (BSSR.JK) Income Statement Analysis – Financial Results
- Imaspro Corporation Berhad (7222.KL) Income Statement Analysis – Financial Results
- Kinovo plc (BILBF) Income Statement Analysis – Financial Results
- Rabbit Holdings Public Company Limited (RABBIT.BK) Income Statement Analysis – Financial Results
Qualigen Therapeutics, Inc. (QLGN)
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.20M | 4.98M | 5.65M | 4.31M | 5.56M | 5.80M | 9.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.21M | 4.30M | 4.33M | 7.19M | 3.98M | 5.42M | 7.90M | 18.45M | 8.91M | 3.48K | 2.14K | 758.00 |
| Gross Profit | -4.50K | 680.80K | 1.32M | -2.88M | 1.58M | 378.39K | 1.87M | -18.45M | -8.91M | -3.48K | -2.14K | -758.00 |
| Gross Profit Ratio | -0.09% | 13.66% | 23.37% | -66.87% | 28.43% | 6.52% | 19.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.21M | 6.84M | 11.72M | 3.55M | 1.21M | 1.32M | 2.87M | 13.29M | 2.26M | 113.93K | 461.55K | 1.39M |
| General & Administrative | 6.10M | 10.84M | 11.72M | 8.02M | 1.51M | 1.05M | 4.78M | 4.88M | 6.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -4.50K | 950.42K | 542.59K | 400.17K | 367.95K | 380.34K | 618.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.09M | 11.79M | 12.27M | 8.42M | 1.88M | 1.43M | 4.78M | 4.88M | 6.40M | 2.16M | 1.65M | 2.01M |
| Other Expenses | -5.21M | 1.13K | 5.45K | 0.00 | 2.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.10M | 18.62M | 23.98M | 17.40M | 3.08M | 1.42M | 7.65M | 18.17M | 8.66M | 2.28M | 2.11M | 3.40M |
| Cost & Expenses | 11.30M | 22.93M | 28.32M | 24.59M | 7.06M | 6.85M | 15.55M | 36.62M | 17.57M | 2.28M | 2.11M | 3.40M |
| Interest Income | 0.00 | 26.65K | 42.69K | 138.80K | 123.05B | 152.04K | 40.23K | 60.88K | 40.88K | 525.00 | 1.68K | 2.91K |
| Interest Expense | 1.52M | 26.65K | 0.00 | 0.00 | 283.10K | 0.00 | 0.00 | 0.00 | 0.00 | 213.52K | 6.08K | 54.64K |
| Depreciation & Amortization | 4.50K | 12.17K | 322.06K | 138.65K | 111.38K | 5.70K | 5.70K | 5.21K | 1.94K | 3.48K | 2.14K | 758.00 |
| EBITDA | -11.30M | -13.84M | -22.66M | -11.16M | -10.02M | -717.86K | -7.86M | -18.38M | -8.79M | -2.26M | -2.09M | -3.40M |
| EBITDA Ratio | -217.12% | -285.64% | -478.41% | -259.27% | -23.10% | -12.37% | -159.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.30M | -17.94M | -22.66M | -11.30M | -1.50M | -1.06M | -15.55M | -36.62M | -17.57M | -2.28M | -2.11M | -3.40M |
| Operating Income Ratio | -217.20% | -360.03% | -400.85% | -262.49% | -27.05% | -18.18% | -159.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.17M | 872.81K | 4.77M | -7.74M | 711.17K | -140.55K | 38.60K | 18.24M | 8.79M | -191.85K | 14.97K | -51.73K |
| Income Before Tax | -12.48M | -21.30M | -17.89M | -20.42M | -1.78M | -1.20M | -7.86M | -18.38M | -9.18M | -2.47M | -2.10M | -3.45M |
| Income Before Tax Ratio | -239.78% | -427.40% | -316.46% | -474.18% | -32.09% | -20.61% | -80.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -4.79K | -265.07K | 5.43K | 619.00 | 4.00K | 4.62K | 5.09K | -5.21K | -1.94K | 1.00 | 0.00 | 0.00 |
| Net Income | -13.42M | -21.03M | -17.90M | -20.42M | -1.79M | -1.20M | -7.86M | -18.38M | -9.18M | -2.47M | -2.10M | -3.45M |
| Net Income Ratio | -257.79% | -422.08% | -316.55% | -474.16% | -32.16% | -20.69% | -80.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.46 | -5.48 | -6.10 | -28.21 | -2.85 | -2.26 | -14.04 | -20.44 | -31.15 | -794.00 | -42.42K | -61.12K |
| EPS Diluted | -2.46 | -5.48 | -6.10 | -28.21 | -2.85 | -2.26 | -14.04 | -20.44 | -31.15 | -794.00 | -42.42K | -61.12K |
| Weighted Avg Shares Out | 5.07M | 3.84M | 2.93M | 723.72K | 627.00K | 530.47K | 560.22K | 899.33K | 294.68K | 3.12K | 62.30 | 62.30 |
| Weighted Avg Shares Out (Dil) | 5.07M | 3.84M | 2.93M | 723.72K | 627.00K | 530.47K | 560.22K | 899.33K | 294.68K | 3.12K | 62.30 | 62.30 |
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100...
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01...
Qualigen Therapeutics, Inc. Announces management changes.
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief...
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the Nasdaq Hearings Panel (“Panel”) has granted an extension...
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the...
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a “Share,” and...
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering
CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a “Share,” and collectively, the...
Why Is Qualigen Therapeutics (QLGN) Stock Down 22% Today?
Qualigen Therapeutics (NASDAQ: QLGN ) stock is falling on Monday as the clinical-stage therapeutics company's shares come off of a massive rally on Friday. That Friday rally resulted in shares of QLGN stock closing out normal trading hours up 109.2%.
Why Is Qualigen (QLGN) Stock Up 141% Today?
Qualigen (NASDAQ: QLGN ) stock is rocketing higher on Friday after the clinical-stage therapeutics company secured a new loan. Qualigen reached an agreement with an investor for a $2 million Senior Note due July 8, 2025 with an 18% annual...
Why Is Qualigen Therapeutics (QLGN) Stock Down 12% Today?
Qualigen Therapeutics (NASDAQ: QLGN ) stock is sliding lower on Monday as the clinical-stage therapeutics company's shares come off of a rally on Friday. That rally saw shares of QLGN stock soar more than 59% higher during normal trading hours.
Source: https://incomestatements.info
Category: Stock Reports